Dr. Barry S. Shea, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 742
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Tufts University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MA license 223946 · RI license MD14714 -
Critical Care Medicine (Internal Medicine) Physician
MA license 223946 -
Internal Medicine Physician
MA license 223946
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
- Wentworth-Douglass Hospital Dover, NH
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 742
- Services billed
- 1,686
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test to measure rate of airflow | 271 | 260 |
| Test to examine how well the lungs exchange gases | 220 | 218 |
| Established patient office or other outpatient visit, 30-39 minutes | 143 | 112 |
| Established patient office or other outpatient visit, 40-54 minutes | 142 | 101 |
| Test to determine lung volumes using gas dilution or washout | 86 | 86 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 72 | 72 |
| Critical care, first 30-74 minutes | 68 | 21 |
| Test to determine lung volumes using sensors | 49 | 49 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 42 | 21 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 21 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pirfenidone | 79 |
| Ofev (nintedanib esylate) | 66 |
| Prednisone Other prescribers in Boston, MA | 63 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boston, MA | 54 |
| Omeprazole Other prescribers in Boston, MA | 49 |
| Mycophenolate Mofetil Other prescribers in Boston, MA | 39 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Boston, MA | 39 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Boston, MA | 38 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in Boston, MA | 30 |
| Montelukast Sodium Other prescribers in Boston, MA | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $517,136 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - PDE4 Phase III trial in IPF patients
Boehringer Ingelheim International GmbH - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim International GmbH - PDE4 Phase III trial in PF-ILD
Boehringer Ingelheim International GmbH - A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or withou…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.